Reblozyl 75 mg powder for solution for injection clinical trials

A Phase 2 Open-Label Study to Evaluate Momelotinib in combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary Myelofibrosis

This study looks at a new drug combination, Momelotinib and Luspatercept (Reblozyl), for people in the UK with myelofibrosis who need regular blood transfusions. The main goal is to see if these medicines can help people stop needing transfusions for at least 12 weeks.